NL-OMON26308已完成Unknown
Individual albuminuria lowering response to dapagliflozin in a decentralized clinical trial in patients with type 2 diabetes mellitus and elevated albuminuria
niversity Medical Center Groningen (UMCG)0 个研究点目标入组 20 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
/A
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Leeftijd = 18 jaar |
排除标准
- •- Diagnose type 1 diabetes |
研究者
相似试验
进行中（未招募）
1 期
Individual urinary protein decreasing effects of dapagliflozin in a remote clinical trial in patients with type 2 diabetes mellitus and elevated urinary protein concentrations.Patients with type 2 diabetes and albuminuria >20 mg/g (2.26 mg/mmol)EUCTR2020-004929-23-NLniversity Medical Center Groningen20
已完成
不适用
Individual albuminuria lowering response to dapagliflozin in a decentralized clinical trial in patients with type 2 diabetes mellitus and elevated albuminuriaAlbuminuria in patients with type 2 diabetes mellitus.100184241001265310029149NL-OMON50915niversitair Medisch Centrum Groningen20
已完成
4 期
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.Diabetes Mellitus Type 2 With ProteinuriaDiabetes ComplicationsAlbuminuriaChronic Kidney DiseasesChronic Kidney Disease Due to Type 2 Diabetes MellitusCKDDiabetesDiabetes MellitusDiabetes Mellitus, Type 2ProteinuriaNCT06374043University Medical Center Groningen20
未知
2 期
Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtrasentaJPRN-jRCT2080221551Abbott Japan Co., Ltd.54
尚未招募
4 期
Comparing Medications for Reducing Kidney Damage in Diabetes: A Study on Dapagliflozin Alone and with EplerenoneCTRI/2024/01/061952Dr Nikhil Kumar